CIK 0001618835 · Non-accelerated filer<br>Smaller reporting company
Evofem Biosciences, Inc.
Sign in to watch- Ticker
- EVFM
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208527075
- Phone
- (858) 550-1900
- Business address
- 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130
- Former names
- Neothetics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2015-11-18 | Locke Kenneth W Chief Scientific Officer | Sale | −6,098 | $8.30 | $51K | 293 |
| 2015-11-18 | Locke Kenneth W Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −4,093 | 23,191 | ||
| 2015-11-18 | Locke Kenneth W Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −2,005 | 11,366 | ||
| 2015-10-15 | Mahaffey George W President and CEO | Shares withheld for taxes | −26,681 | $8.60 | $229K | 171,040 |
| 2015-09-23 | ZEINI HANI M Director | Grant or award · Stock Option (Right to Buy) | +10,179 | 10,179 | ||
| 2015-09-23 | Nugent Jeffrey M Director | Grant or award · Stock Option (Right to Buy) | +10,179 | 10,179 | ||
| 2015-09-18 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise | +1,000 | $1.34 | $1K | 11,848 |
| 2015-09-18 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Sale | −1,000 | $12.20 | $12K | 10,848 |
| 2015-09-18 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise · Stock Option (Right to Buy) | −1,000 | 50,182 | ||
| 2015-09-01 | Knudson Susan A. Chief Financial Officer | Option exercise | +3,000 | $1.22 | $4K | 3,492 |
| 2015-09-01 | Knudson Susan A. Chief Financial Officer | Sale | −3,000 | $11.33 | $34K | 492 |
| 2015-09-01 | Knudson Susan A. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −3,000 | 30,718 | ||
| 2015-08-07 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise | +1,000 | $1.34 | $1K | 11,848 |
| 2015-08-07 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise · Stock Option (Right to Buy) | −1,000 | 51,182 | ||
| 2015-08-07 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise | +1,000 | $1.22 | $1K | 11,848 |
| 2015-08-07 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Sale | −1,000 | $12.88 | $13K | 10,848 |
| 2015-08-07 | Kemmerer Christopher VP, Pharma Dev & Manufacturing | Option exercise · Stock Option (Right to Buy) | −1,000 | 1,710 | ||
| 2015-06-16 | Kamdar Kim P. Director | Grant or award · Stock Option (Right to Buy) | +23,940 | 23,940 | ||
| 2015-06-16 | Kamdar Kim P. Director | Grant or award · Stock Option (Right to Buy) | +12,450 | 12,450 | ||
| 2015-06-16 | JANNEY DANIEL Director | Grant or award · Stock Option (Right to Buy) | +23,940 | 23,940 |
Page 15 of 20 · 383 trades